| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| R&D Expense | $138.3M | +101.9% |
| SG&A Expense | $30.7M | +113.1% |
| Operating Income | -$169.1M | -103.8% |
| Net Income | -$161.2M | -107.7% |
| EPS (Basic) | -$18.56 | +82.4% |
| EPS (Diluted) | -$18.56 | +82.4% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $46.7M | +22.2% |
| Short-term Investments | $258.4M | +266.3% |
| Current Assets | $324.7M | +183.3% |
| Total Assets | $479.5M | +250.2% |
| Current Liabilities | $16.2M | +1.9% |
| Total Liabilities | $21.1M | -2.7% |
| Stockholders' Equity | $458.4M | +336.7% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$138.1M | -75.3% |
| Capital Expenditures | $473K | -38.6% |
| Investing Cash Flow | -$323.2M | -300.1% |
| Financing Cash Flow | $469.8M | +298.0% |
| Free Cash Flow | -$138.6M | -74.2% |